Halozyme Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Halozyme Therapeutics announces its 2026 Annual Meeting agenda, highlighting robust 2025 financial performance, strategic acquisitions, and significant partner advancements.
NASDAQ
Halozyme Therapeutics has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.
NASDAQ
Halozyme Therapeutics will hold its 2025 Annual Meeting of Stockholders online on May 1, 2025, to elect directors, vote on executive compensation, and ratify the selection of its accounting firm.
NASDAQ
Halozyme Therapeutics has filed definitive additional proxy materials with the SEC.
NASDAQ
DEF 14A: Halozyme Therapeutics Announces 2024 Annual Meeting of Stockholders, Outlines Key Proposals
Halozyme Therapeutics is set to hold its 2024 Annual Meeting of Stockholders virtually on April 25, 2024, to vote on director elections, executive compensation, and corporate governance matters.